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Abstract
Background: Leber’s hereditary optic neuropathy (LHON) is caused by mutations in the complex I subunits of the
respiratory chain. Although patients have been treated with idebenone since 1992, the efficacy of the drug is still a
matter of debate.
Methods: We evaluated the effect of idebenone in fibroblasts from LHON patients using enzymatic and
polarographic measurements.
Results: Complex I activity was 42% greater in treated fibroblasts compared to controls (p = 0.002). Despite this
complex I activity improvement, the effects on mitochondrial respiration were contradictory, leading to impairment
in some cases and stimulation in others.
Conclusion: These results indicate that idebenone is able to compensate the complex I deficiency in LHON patient
cells with variable effects on respiration, indicating that the patients might not be equally likely to benefit from the
treatment.
Background
Leber’s hereditary optic neuropathy (LHON, OMIM
#535000), the most frequent mitochondrial DNA-related
disorder, is characterized by maternal inheritance and
by incomplete penetrance with male predominance
[1,2]. The age of onset is highly variable but typically
situated between 15 and 30 years. The acute or subacute
onset of the optic neuropathy, due to the specific degen-
erescence of retinal ganglion cells, generally begins in
one eye and affects the other one within a few weeks or
months. Three main mitochondrial DNA point muta-
tions (m.11778 G > A in the ND4 gene, m.3460 G > A
in the ND1 gene, and m.14484 T > C in the ND6 gene)
are responsible for the disease in 95% of patients [1,2].
These mutations affect the protein subunits of complex
I of the mitochondrial respiratory chain (NADH dehy-
drogenase). Fibroblasts from patients carrying one of the
three mutations have on average 61% residual complex I
activity, associated with defective OXPHOS efficiency
and impaired ATP synthesis [3].
Idebenone (2,3-dimethoxy-5-methy-6-(10-hydroxy)-
decyl-1,4-benzoquinone), an analog of coenzyme Q,
facilitates electron transfer along the respiratory chain.
The beneficial effects of this molecule remain contro-
versial since some reports have claimed it leads to fas-
ter visual recovery [4-6], whereas other authors have
found that idebenone treatment did not alter the
course of the disease [7]. A recent randomized con-
trolled trial in 85 patients with LHON showed that
patients with discordant visual acuities were the most
likely to benefit from idebenone treatment [8]. Another
recent retrospective clinical study in 103 LHON
patients showed that early and prolonged idebenone
treatment may improve significantly the frequency of
visual recovery [9] but, within the treated group, only
a proportion of patients was shown to respond to the
treatment. To date, the biological effects of idebenone
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although idebenone is often administered in cases of
LHON. In order to better understand the biological
bases of these variable impacts of idebenone in LHON
patients, we tested the effects of idebenone on complex
I activity and mitochondrial respiration in fibroblasts
from patients harbouring one of the three main muta-
tions associated with the disease.
Methods
Ethical approval
This work was approved by the Ethical Committee of
the University Hospital of Angers (N°2011/39).
Patients
Fibroblasts were cultured from skin biopsies taken after
obtaining informed consent from nine patients (eight
men and one woman), each carrying one of the three
mutations associated with LHON, and three controls.
The LHON mutations and haplotyping were determined
in our diagnostics laboratory. The heteroplasmic levels
were measured at the same cellular passage numbers as
those used for the experiments (Table 1).
Cell culture
The cells were cultivated in 2/3 Dulbecco’sm i n i m u m
essential medium (Gibco, Cergy-Pontoise, France) sup-
plemented with 1/3 Amniomax (Gibco, Cergy-Pon-
toise, France) and 10% foetal calf serum (PAA,
Pasching, Austria). All experiments were conducted on
cells at less than 20 passages to avoid bias due to cell
senescence. Ethanol (used as vehicle) or 10 μMi d e b e -
none (Santhera Pharmaceutical, Liestal, Switzerland)
was added 24 h before each experiment. At this con-
centration, idebenone has been found to be effective as
an antioxidant [10] and capable of stimulating the
mitochondrial respiratory chain [11]. Unfortunately, we
were not able to perform oxygen consumption in
patients 7, 8 and 9.
Enzymatic activities
The activity of the mitochondrial respiratory chain com-
plexes was measured on cell homogenates in a cell buf-
fer (250 mM saccharose, 20 mM tris[hydroxymethyl]
aminomethane, 2 mM EGTA, 1 mg/mL bovine serum
albumin, pH 7.2), at 37°C using a Beckman DU 640
spectrophotometer (Beckman Coulter, Brea, CA, USA).
The cellular protein content was determined with the
Bicinchoninic assay kit (Uptima, Interchim, Montluçon,
France) using bovine serum albumin as standard. Com-
plex I (NADH ubiquinone reductase, EC 1.6.5.3) activity
was measured according to a procedure described else-
where [12] and adapted using DCPIP to avoid the inhi-
bition of complex I activity by decylubiquinol [13]. Cells
were disrupted by two freezing-thawing cycles, washed,
centrifuged for one minute at 16 000 g, re-suspended in
the cell buffer (50 μL/10
6 cells), and sonicated (6 × 5 s)
on ice. Complex I activity was immediately assayed on
cell lysate (0.25 × 10
6 cells) in the KH2PO4 buffer (80
mM, pH 7.4), containing 1 mM KCN, 2 mM NaN3,
0.075 mM DCPIP and 0.1 mM of decylubiquinone.
After 2 min of incubation, 0.3 mM NADH was added
and the rate of disappearance of DCPIP was monitored
at 600 nm. Rotenone (5 μM) was added during the mea-
surement to determine the background rate, and the
activity was calculated using εDCPIP = 19.1 mM
-1 cm
-1.
Specific rotenone-sensitive complex I activity was
expressed in mIU (nanomoles of DCPIP/min/mg pro-
tein). Citrate synthase (EC 2.3.3.1) activity was assayed
by a standard procedure [14]. Specific enzymatic activ-
i t i e sw e r ee x p r e s s e di nm I U ,i . e .n a n o m o l e so f5 - 5 ’-
dithiobis (2-nitrobenzoic acid), DTNB/min/mg protein.
All experiments were performed in triplicate on inde-
pendent cell cultures.
Oxygen consumption
The respiratory rates were measured on cells permeabi-
lized by incubation for 2 min with digitonin (15 μg/mil-
lion cells) and re-suspended in the respiratory buffer
Table 1 Mitochondrial genetic profile of the LHON fibroblasts
PATIENTS Age (years) Sex mtDNA mutation Heteroplasmy level Haplogroup
1 22 M m.3460G > A 100% J
2 30 M m.11778G > A 74% V
3
a 43 F m.11778G > A 100% U
4 20 M m.11778G > A > 90% K
5 47 M m.11778G > A 100% H
6 32 M m.11778G > A 100% V
7 44 M m.11778G > A 81% J
8 52 M m.11778G > A 100% H
9 43 M m.14484T > C 100% H
aAlthough Patient 3 had a typical LHON clinical presentation, she was also known to be carrying an OPA1 gene mutation (p.Ile382Met). However, the
pathogenicity of this mutation has not been fully demonstrated and its contribution to the clinical expression of LHON in this patient is unknown.
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KCl, and 5 mM MgCl2). The respiratory rates of 3-5 ×
10
6 cells were recorded at 37°C in 2-ml glass chambers
using a high-resolution Oxygraph respirometer (Oro-
boros, Innsbruck, Austria). Respiration was started with
complex I-dependent substrates (5 mM malate/5 mM
pyruvate). Complex I-coupled state 3 respiration was
measured by adding 0.5 mM NAD
+/1.5 mM ADP.
Then, 10 mM succinate were added to reach maximal
coupled respiration, and 10 μM rotenone were injected
to obtain the complex II-coupled state 3 respiration.
Oligomycin (8 μg/mL) was added to determine the
uncoupled state 4 respiration. Finally, FCCP (1 μM) was
added to control the permeabilisation of the fibroblasts.
All experiments were performed in duplicate on inde-
pendent cell cultures.
Statistical analysis
Vehicle-treated and idebenone-treated fibroblasts from
LHON patients and controls were compared using a
non-parametric Mann-Whitney U test; differences were
considered significant at p < 0.05.
Results
Idebenone at 10 μM partially restores complex I
enzymatic activity
T h ea c t i v i t yo fN A D Hu b i q u i n o n eo x i d o r e d u c t a s ew a s
lower in fibroblasts from LHON patients as compared
to controls (56.7 ± 10.5 in LHON fibroblasts versus
108.4 ± 7.4 in controls; p = 0.01) (Figure 1A). Idebenone
at 10 μM induced variable increases in complex I enzy-
matic activity in fibroblasts from LHON patients,
whereas it had no such effect on control fibroblasts (Fig-
ure 1A). The pooled results of fibroblasts from LHON
patients treated with idebenone showed a 42% increase
in complex I enzymatic activity (81.0 ± 15.0 in fibro-
blasts from LHON patients treated with idebenone ver-
sus 56.7 ± 10.5 in vehicle-treated fibroblasts; p = 0.002)
(Figure 1B).
Idebenone at 10 μM induces contradictory effects on
respiratory chain activity
The activity of the mitochondrial respiratory chain was
analysed by polarographic measurements of complex I-
driven respiration. The I/(I+II) ratio indicated the frac-
tion of complex I-driven respiration with respect to the
maximal respiratory rate controlled by complexes I and
II. The I/(I+II) ratio was significantly lower in fibroblasts
from six LHON patients compared to controls (0.50 ±
0.05 versus 0.72 ± 0.08; p = 0.02) (Figure 2A). Idebenone
had no effect on complex I-driven respiration in con-
trols. However, in fibroblasts from LHON patients the
response to idebenone proved to be contradictory. Thus,
in fibroblasts from Patients 1, 3 and 6, complex I-driven
respiration was impaired, whereas it was stimulated in
fibroblasts from Patients 2, 4 and 5 (Figure 2B). The
analysis of these two groups of fibroblasts revealed a
deleterious effect of idebenone in the first group, with a
42% reduction in complex I-driven respiration compared
to controls (p = 0.04), and a stimulating effect of idebe-
none in the second group, with a 16% increase com-
pared to controls (p = 0.04) (Figure 2C).
Discussion and conclusions
Previous studies of LHON fibroblasts have shown sig-
nificant complex I impairment [3,15]. These results
attest that, although the clinical expression is mostly
limited to retinal ganglion cells, the OXPHOS defect is
probably more generalized as has also been shown by
Barbiroli et al. [16] who found defective energy meta-
bolism in the muscle and brain of LHON patients by
using 31P-MRS in vivo. Thus, fibroblasts represent an
interesting model to explore the LHON-associated
OXPHOS defect and to research molecules able to
compensate the defect.
This study demonstrates the impact of idebenone on
respiratory chain activity in fibroblasts from nine LHON
patients. Indeed, idebenone increased complex I enzy-
matic activity in these fibroblasts by 42% compared to
controls (p = 0.002). This idebenone effect on complex I
enzymatic activity was found to be shared by fibroblasts
carrying the same m.11778 G > A mutation in 7 differ-
ent genetic backgrounds (inter-individual variability);
this idebenone effect was also found to be shared by
fibroblasts carrying the 3 main LHON mutations (inter-
mutation variability). The action of idebenone was not
due to an increase either of complex I or of the mito-
chondrial mass. Indeed, two subunits of complex I, i.e.
NDUFA9 and NDUFB8 in western blot, and the citrate
synthase activity were not affected by the treatment
(Additional file 1: Figure S1).
Various types of action have been ascribed to idebe-
none in the literature. Experiments with idebenone have
led to some conflicting results. Thus, the oral adminis-
tration of idebenone for 3 days has been reported to sti-
mulate mitochondrial respiration linked to complexes I
and II in the rat brain [11]. In contrast, idebenone has
been described as a weak substrate for complex I activ-
ity [17,18]. Idebenone has also been shown to bind to a
rotenone-insensitive site, i.e. the non-physiological iron-
sulphur N2 site, thus leading to higher NADH oxidation
but without complete reduction [19]. However, in these
latter observations, idebenone was added in the incuba-
tion medium directly only during the experiments. The
administration of idebenone over a period of 3 days [11]
may have led to better metabolization of the drug,
allowing it to enter cells and activate signalling pathways
such as MAP kinase [10].
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effect of idebenone on mitochondrial activity in fibro-
blasts from six LHON patients led to contradictory
results: a 16% increase in complex I-driven respiration
in three cases, and a 42% decrease in the other three
cases. The increase observed might correspond to the
idebenone-induced improvement similar to that
reported in intact rat brain mitochondria [11], whereas
the opposite response might be explained by an increase
of electron escape du to enhanced idebenone fixation at
a non-specific site [19].
The variability of the effect of idebenone on complex I
activity may be linked to the genetic variability of the
LHON patients. However, the number of patients in our
study was too small to reveal the possible influence of
the haplogroup, the mutation type or the mutation level
on the treatment. A larger cohort of LHON patients
would be necessary to assess the influence of these
factors.
To our knowledge, this is the first demonstration
that idebenone directly influences mitochondrial
respiratory chain activity in LHON patients. Idebenone
increases the enzymatic activity of complex I and acts
on the complex I-driven respiration rate, modifying the
balance between the electron fluxes provided by com-
plexes I and II. It is tempting to speculate that the
variability of the biological response to idebenone in
fibroblasts from LHON patients may explain the dis-
cordant results observed in some clinical studies
[6,7,20]. Our results suggest that only a fraction of
LHON patients may benefit from the improved
respiration afforded by idebenone. If this finding is
Figure 1 The effect of idebenone on complex I activity. A. Complex I (CxI) activity in fibroblasts from LHON patients (n = 9) and controls (n
= 3) treated with vehicle (grey bars)o r1 0μM idebenone (black bars) 24 h before the analysis. The enzymatic activity was standardized in terms
of citrate synthase (CS) activity, indicative of mitochondrial mass and expressed as the percentage of activity of one control fibroblast used as
reference in all experiments (CxI/CS(%)). B. Pooled results from fibroblasts from LHON patients and controls. Results are expressed as mean values
± SD. Statistical significance: **p < 0.01 compared with vehicle-treated fibroblasts from LHON patients. C = Controls and P = Patients.
Angebault et al. BMC Research Notes 2011, 4:557
http://www.biomedcentral.com/1756-0500/4/557
Page 4 of 6substantiated by a more extensive study, a preliminary
investigation of the impact of idebenone on fibroblasts
from LHON patients may be useful to select poten-
tially “good responders” to the treatment.
Availability of supporting data
The data sets supporting the results of this article are
included within the article and its additional file.
Additional material
Additional file 1: Figure S1. The effect of idebenone on complex I
quantity and mitochondrial mass. A. Quantity of two subunits of
complex I, NDUFA9 and NDUFB8, in fibroblasts from LHON and controls
treated with vehicle (V) or 10 μM idebenone (I10) 24 hours before the
analysis. B. Citrate synthase activity in fibroblasts from LHON patients (n
= 9) and controls (n = 3) treated with vehicle (grey bars) or 10 μM
idebenone (black bars) 24 hours before the analysis. The enzymatic
activity was expressed as the percentage of activity of one control
fibroblast used as reference in all experiments.
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hereditary optic neuropathy; mtDNA: Mitochondrial DNA; ND: NADH
dehydrogenase; NUR: NADH ubiquinone reductase; OMIM: Online Mendelian
Inheritance in Man; OPA1: Optic atrophy protein 1; OXPHOS: Oxidative
phosphorylation.
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